Results research

Concall Intelligence

Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.

Open reported results

Matching calls

After selected filters

Transcript verified

Official transcript summaries on this page

Preliminary briefs

Presentation evidence, clearly labelled

Processing

Transcript filed or call source found

Tracked companies

Watchlist or portfolio matches

Management evidence

Generated 22 Oct, 5:45 am IST · click a summary to inspect source-linked evidence for this results quarter.

Clear filters

Company	Call and sources	Reported result	Management outlook	Evidence-led conclusion
IGIL International Gemmological Institute (India) Limited Services · Large	Sept 2026 21 Oct 2026 Call source found PPT Recording	Excellent 100/100	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
E2E E2E Networks Limited IT · Small	Sept 2026 21 Oct 2026 Transcript verified Transcript PPT Recording	Good 55/100	Optimistic outlook Broadly unchanged No measurable guidance	E2E Networks delivered robust financial performance in Q2 FY27 with triple-digit YoY revenue growth and margin expansion, supported by Blackwell GPU deployment and improved utilization. Management maintains a disciplined approach to capex and avoids speculative guidance. Evidence summary ready
IOLCP IOL Chemicals and Pharmaceuticals Limited Industrials · Small	Sep 2026 19 Oct 2026 Transcript filed Transcript Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
TEMPSENS Tempsens Instruments (India) Limited Industrials · Micro	Sep 2026 19 Oct 2026 Transcript filed Transcript PPT Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
METROPOLIS Metropolis Healthcare Limited Pharma · Micro	Sep 2026 19 Oct 2026 Transcript verified Transcript PPT Recording	Result pending No matching current-quarter result row	Optimistic outlook No comparable prior call No measurable guidance	Management projects continued profitable and sustainable growth, leveraging technology, science, and network expansion. Focus on specialty tests, TruHealth, and D2C channels, alongside strategic M&A, aims to outpace industry growth and create shareholder value. Evidence summary ready
NOVARTIND Novartis India Limited Pharma · Small	Sep 2026 19 Oct 2026 Transcript filed Transcript PPT Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
INDOBORAX Indo Borax & Chemicals Limited Industrials · Small	Sep 2026 19 Oct 2026 Transcript filed Transcript PPT Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
HTEL Hy-Tech Engineers Limited Industrials · Micro	Sep 2026 19 Oct 2026 Transcript filed Transcript PPT Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
ESDS ESDS Software Solution Limited IT · Small	Sep 2026 19 Oct 2026 Transcript filed Transcript Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
INDIAGLYCO India Glycols Limited FMCG · Micro	Sep 2026 10 Oct 2026 Preliminary brief Transcript PPT Recording	Result pending No matching current-quarter result row	Optimistic outlook Broadly unchanged No measurable guidance	The company demonstrates strong growth in both spirits and bio-fuels, driven by premiumization, strategic partnerships, and integrated manufacturing. Margin expansion and improving capital returns support the current thesis, though execution on new market expansion and premium portfolio scale-up remains key. Evidence summary ready
GRANULES Granules India Limited Pharma · Large	Sept 2026 6 Oct 2026 Transcript filed Transcript Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending
SYMBIOTEC Symbiotec Pharmalab Limited Pharma · Micro	Sep 2026 2 Oct 2026 Transcript filed Transcript PPT Recording	Result pending No matching current-quarter result row	Outlook pending No comparable prior call Guidance pending	The available source has not produced sufficient structured evidence. Summary pending

Method: Deterministic quarterly-result score from reported growth, margin direction and operating leverage. Derived only from extracted, source-linked management evidence. Pending is shown when evidence is insufficient. Measurable claims are separated from general commentary and retain outcome status when later evidence exists. Transcript-verified summaries rank above preliminary presentation briefs and source-only call evidence. Preliminary briefs are replaced automatically when an official transcript is processed. Management outlook and colours describe extracted commentary evidence; they are not buy or sell labels.